Quality of life for people with CLL treated with acalabrutinib in France (PLATON database retrospective analysis)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis using patient records from the French PLATON database to describe quality of life from treatment start through 12 months in adults with CLL treated with acalabrutinib, either alone or with obinutuzumab. The analysis will include treatment‑naïve patients recorded in PLATON, including those who discontinue acalabrutinib before 12 months. Quality-of-life measures captured in the database will be summarized over time and described by key clinical and demographic subgroups. No new treatments or procedures are performed because the project analyzes existing routine-care data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The following patients will be eligible for inclusion in the AQUALIS study :
* -Patient enrolled in the PLATON database
* -Patient ≥18 years old
* -Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
* -Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
* -Patients who started Acala but discontinued before 12 months are also included.
* Exclusion criteria:
* -Pregnant women
* -Patients under protection of justice
* -Patients over the age of 18 and unable to express their non-opposition
* -Patients with prior CLL treatments

Exclusion Criteria:

Where it's running

• Research Site
  Saint-Affrique, France Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Acalabrutinib for CLL in routine care in Belarus

  This project will see how well acalabrutinib works and how safe it is for adults with chronic lymphocytic leukemia treated in routine clinical practice in Belarus.

  Recruiting at 3 sites AstraZeneca · Grodno and 3 other locations · NCT07288515

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Intermittent versus continuous venetoclax with acalabrutinib in CLL/SLL

  This will test whether giving venetoclax intermittently or continuously together with acalabrutinib helps people with previously untreated CLL or SLL.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07014917

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.